Shares of Biotechnology company Immunovant climbed 9.6% this afternoon. Here are some quick facts to get you started if you are interested in the stock:
-
Immunovant has logged a 97.2% 52 week change, compared to 20.4% for the S&P 500
-
IMVT has an average analyst rating of buy and is -15.15% away from its mean target price of $50.23 per share
-
Its trailing earnings per share (EPS) is $-1.96, which brings its trailing Price to Earnings (P/E) ratio to -21.7. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $-1.93 and its forward P/E ratio is -22.1
-
The company has a Price to Book (P/B) ratio of 22.24 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The company's free cash flow for the last fiscal year was $-188390000 and the average free cash flow growth rate is -50.7%